Great sleuthing hottod!
The issue of extraordinary cost and little strong evidence for comparative efficacy makes it very important that the SynPath trial is rock solid. If it is as successful as we think it will be, surely the market competitors, such as this, will be blown away by its low cost.
- Forums
- ASX - By Stock
- Competitors to PNV
Great sleuthing hottod!The issue of extraordinary cost and...
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PNV (ASX) to my watchlist
(20min delay)
|
|||||
Last
$2.45 |
Change
0.010(0.41%) |
Mkt cap ! $1.691B |
Open | High | Low | Value | Volume |
$2.45 | $2.51 | $2.43 | $5.243M | 2.122M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 35541 | $2.45 |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
$2.46 | 2681 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
2 | 8773 | 2.450 |
3 | 6522 | 2.430 |
1 | 2681 | 2.420 |
3 | 6302 | 2.410 |
3 | 5925 | 2.400 |
Price($) | Vol. | No. |
---|---|---|
2.460 | 2681 | 1 |
2.470 | 2681 | 1 |
2.480 | 23333 | 3 |
2.490 | 12681 | 2 |
2.500 | 92672 | 4 |
Last trade - 16.10pm 28/06/2024 (20 minute delay) ? |
Featured News
PNV (ASX) Chart |
The Watchlist
LU7
LITHIUM UNIVERSE LIMITED
Alex Hanly, CEO
Alex Hanly
CEO
SPONSORED BY The Market Online